Tadalafil
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prostatic Hyperplasia
Conditions
Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Trial Timeline
Dec 1, 2015 → Jun 1, 2020
NCT ID
NCT02252367About Tadalafil
Tadalafil is a approved stage product being developed by Eli Lilly for Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT02252367. Target conditions include Prostatic Hyperplasia, Lower Urinary Tract Symptoms.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02252367 | Approved | Completed |
| NCT02224846 | Approved | Completed |
| NCT01326117 | Approved | Withdrawn |
| NCT01324999 | Phase 2/3 | Completed |
| NCT01183650 | Phase 1 | Completed |
| NCT01066845 | Pre-clinical | Completed |
| NCT00822354 | Pre-clinical | Completed |
| NCT00157326 | Phase 2 | Completed |
| NCT00333281 | Approved | Completed |
| NCT00422578 | Approved | Completed |
| NCT00421083 | Phase 3 | Completed |
| NCT00547417 | Phase 3 | Completed |
| NCT00547599 | Approved | Completed |
Competing Products
20 competing products in Prostatic Hyperplasia